Richter, AbbVie partner to develop new dopamine receptor modulators
Image by gedeonrichter.com
Hungarian pharmaceutical company Gedeon Richter announced a collaboration with U.S. peer AbbVie to develop new dopamine receptor modulators that could be used to treat neuropsychiatric diseases, according to a report by state news wire MTI.
The new co-development and license agreement to research, develop, and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases "is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development", Richter said.
Richter noted that it has collaborated with AbbVie on central nervous system projects, including its antipsychotic cariprazine, for 15 years.
AbbVie's chief scientific officer Tom Hudson said the company will collaborate with Richter to "continue to build on our research that seeks to provide additional insights into our understanding of cariprazine's clinical pharmacology and explore novel chemistry to identify new dopamine receptor modulators".
Under the terms of the agreement, the collaboration includes both preclinical and clinical R&D activities with shared financing by the parties. Richter will receive an upfront cash payment, along with potential future development, regulatory and commercialization milestones. In addition, Richter may also receive sales-based royalties. AbbVie will have worldwide commercialization rights except in Richter's traditional markets, such as Europe, Russia, the other CIS countries, and Vietnam.
The transaction is expected to close in the second quarter of 2022, "subject to the satisfaction of customary closing conditions, including applicable regulatory approvals", Richter said.
Moody's Affirms Budapest's 'Baa3' Rating
Bulgaria's Household Income, Spending Rise 20% in 2023
Job Fair and Career Prep at Corvinus Starts Tomorrow
Spago Budapest Offering Unique Sunday Brunch Experience
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
